Our partner is a clinical-stage biotechnology company focused on delivering novel therapies for autoimmune diseases with the heaviest patient burdens. They are rapidly developing a pipeline of medicines targeted to the specific molecular dysregulations underlying severe autoimmune conditions, unlocking new treatment options for patients who are underserved by existing therapies.

This critical hire was an executive leader responsible for establishing the global regulatory strategy for the company’s product pipeline and provided strategic leadership to oversee and direct all regulatory activities. They developed and implemented strategies for investigational product development through post-approval activities to ensure achievement of business objectives.